SCHOFIELD, Wis., June 10, 2009 (GLOBE NEWSWIRE) -- PuraMed Bioscience, Inc. (OTCBB:PMBS), a pharmaceutical company engaged in the development and marketing of a line of revolutionary, new, non-prescription medicines targeting major consumer health needs including the treatment of migraine headaches, insomnia and tension-type headaches, announced today that they have completed their first production run of their LipiGesic(tm)-M migraine relief product for commercial resale. This will provide the company with its first opportunity to generate revenue.
